Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy

British Journal of Cancer

Volumn 117, Issue 7, 2017, Pages 921-924

  Tay, Rebecca Y ^a   Blackley, Elizabeth ^a   McLean, Catriona ^a,b   Moore, Maggie ^a   Bergin, Peter ^c   Gill, Sanjeev ^a   Haydon, Andrew ^a,b  

^a Alfred Health ^*  (Australia)

^b MONASH UNIVERSITY   (Australia)

^c Heart Centre   (Australia)

Author keywords

anti thymocyte globulin; ATGAM; checkpoint inhibitor; glioblastoma; immune related adverse events; immunotherapy; myocarditis; nivolumab

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CREATINE KINASE; INFLIXIMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; NIVOLUMAB; PREDNISOLONE; TEMOZOLOMIDE; THYMOCYTE ANTIBODY; TROPONIN I; ANTINEOPLASTIC AGENT; DACARBAZINE; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CYTOPENIA; DAILY LIFE ACTIVITY; DISEASE COURSE; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; FULMINANT MYOCARDITIS; GLIOBLASTOMA; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HEART VENTRICLE BIGEMINY; HEART VENTRICLE TACHYCARDIA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LOW DRUG DOSE; MIDDLE AGED; MYOCARDITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; CHEMICALLY INDUCED; CHEMORADIOTHERAPY; HORSE; IMMUNOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DACARBAZINE; FEMALE; GLIOBLASTOMA; HORSES; HUMANS; MIDDLE AGED; MYOCARDITIS;

EID: 85029897842     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2017.253     Document Type: Article

References (17)

1. Ahmed T, Pandey R, Shah B, Black J (2015) Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy. BMJ Case Rep: pii: bcr2014208102. Available at: http://doi.org/10.1136/bcr-2014-208102.
2. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373: 1627-1639.
3. Chmiel KD, Suan D, Liddle C, Nankivell B, Ibrahim R, Bautista C, Thompson J, Fulcher D, Kefford R (2011) Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol 29: 237-240.
4. Ferris RL, Blumenschein Jr G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375: 1856-1867.
5. Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ (2016) Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 4: 50.
6. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375: 1749-1755.
7. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373: 23-34.
8. Lexicomp, Inc (2017) Antithymocyte globulin (equine, Atgam): Drug information. Lexicomp, Inc.
9. Läubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A (2015) Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 3: 11.
10. Merrill SP, Reynolds P, Kalra A, Biehl J, Vandivier RW, Mueller SW (2014) Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient. Ann Pharmacother 48: 806-810.
11. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373: 1803-1813.
12. Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD (2015) Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26: 2375-2391.
13. Pagès C, Gornet JM, Monsel G, Allez M, Bertheau P, Bagot M, Lebbé C, Viguier M (2013) Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res 23: 227-230.
14. Postow MA (2015) Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 35(76): 76-83.
15. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, LebbéC, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372: 320-330.
16. Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JA, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD (2017) Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 18(3): 312-322.
17. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller Jr WH, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4): 375-384.